The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Hi Borsaci, I am interested in your post and would like to inform myself more about the situation. Where can I look to see the options they exercised and still hold, and how long they have held them after they were eligible to be exercised please?
Peel
Andybe4, in answer to your question, enrolling patients in trials is valuable to hospitals but time-consuming. RM indicated that recruitment has dipped month on month from August to Sept due to the hospitals being too busy to do the time-consuming bit in such big numbers. Although sounding paradoxical, I can confirm that has been the situation on the ground during periods of vastly increased admissions with COVID. Frustrating reality. Looking at the graph he showed of recruitment, it does seem very likely that last patient will be recruited in November as he indicated probable yesterday. Hope that helps and sorry to hear you currently carry a paper loss. I believe it is SPRINTER that will make a huge difference to that position, if it replicates the P2 data. GLA, Peel
Congrats and respect Tyla
"The stock market is a device for moving money from the impatient to the patient" Buffett
I am playing this one long and looking to add. Didn't think I'd get the chance at these levels again
Words -> worlds
:-)
Bobfraeberks, I note 123K out of 488K global cases of COVID yesterday were in the USA (25%). This is the main global market and sadly due to world leading obesity levels and relatively low vaccine uptake, leads on hospitalisations. 25% of words deaths yesterday also sadly (2.2K of 8.8K globally). A reasonable choice of a country to mention discussions with regulators
Also I think positive that we are having data reviewed prior to deciding about progression to A2P3. Proof positive that we are not yet excluded, like so many have been
Tough to hear that not even top line results until early 2022. It fits with a modest delay to the last patient enrolled RNS now expected November. On the other hand, this marks the first hard data of our recruitment progress. Almost 80% of 610 enrolled. Must be enrolling quicker now if less than 2 months expected to pick up the last 20+%
This is solid news in RNS. I am delighted
Despite my modest £1.68 guess, I still can’t sleep!! Feels like could be a big day and if not, only 3 months and 0 days left in H2
Helen, thanks for picking up that subtlety of language. I hope and think I am registered to watch it live now
£1.68
Doc, I like a scoop but had to pause when I noticed the tables are £4550 plus VAT (for 10). Saying that, if there is a similar announcement for P3 SPRINTER as we had from P2, we may need end up needing a few tables to have a chance to buy the Synairgen table some well earned drinkies!
Nice Ducati, major exposure orchestrated by RM after a long period of silence. In a week with planned publicity with interim results. And we are due our last patient RNS for SPRINTER fairly soon. FOMO for this share IMO
Yes Ghia and thank goodness for the FDA, who cut a third off the number for our P3 trial. Without that, we would have another 4 and a half months of recruiting to do!
Thanks Matterhorn. If that ends up as the reality, we should get a last patient Sprinter RNS over the coming week or two. Fingers crossed. It'll have to be fairly soon for a P3 readout in H2 as indicated
Hi All, does anyone know any more detail on when we can expect the last patient recruited RNS for Sprinter? I note on the NIH website that it stated estimated primary completion date 1st Oct.
https://clinicaltrials.gov/ct2/show/study/NCT04732949
Primary completion date is when the last data is harvested on the last patient needed for primary outcomes (28-35 days post recruitment). Yet I seem to remember there was talk previously of needing until Nov to get the last patient recruited. Can anyone point me in the direction of more accurate data? Thanks in advance. Peel
Thanks JohnB and mact, I can get it to open with the link you said mact, in the location JohnB said. We await news about whether we take the leap into a genuinely huge A2P3. It is certainly powered to find efficacy that is above that of Regen-Cov
Thanks Titania,
JohnB, I can click through the over 18, diagnosed last 9 days and in US buttons but then only get given the phone number to get in touch with the team. I cannot see any mention of inhailed, or any other type of treatment. This is clearly the new website for A2P3 so good news that the October start is still on. We don't have confirmation that we have made the move to A2P3 just yet? Can't be long though as starting soon. And no bad news from the changes as all the patient info sheets for all the trial drugs are removed from the site at the moment. Fingers crossed, would be nice to be included. Our best get must still reside with our multinational P3, which has strong P2 data. Great that the USA might choose us as one of 3 drugs to trial at home for P3.
Thanks Matterhorn, though would have loved to hear the Q and A live